Remove tag digital-health-innovation-2020
article thumbnail

Grand Rounds January 12, 2024: Design and Implementation of a Weighted Lottery to Equitably Allocate Scarce Covid-19 Resources (Erin K. McCreary, PharmD, BCIDP)

Rethinking Clinical Trials

The COVID Therapeutics Committee worked with the state health department to develop a policy for fair allocation of scarce medications to treat COVID-19. The first drug that used the new process was Remdesivir in May 2020. The first monoclonal antibody (mABs) treatment for treatment of COVID-19 was approved in November 2020.

article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

N o one industry is ever quite like another, but there are some valuable lessons for pharma marketing from examining how the financial sector uses technology, builds brands on social channels and approaches digital content. The key is adapting existing legacy and traditional printed material for the digital environment.”.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New Rare Disease Drugs and Research Advancements

XTalks

In 2020, 31 out of 53 novel drug approvals were for rare or orphan diseases​​. Despite high price tags of a couple of million dollars, gene therapy makers say they are working to ensure patients are able to access the treatments through patient assistance programs developed in conjunction with the support of governments.

article thumbnail

What is modular content and why do pharma marketers need it NOW?

pharmaphorum

Modular content is an established practice among digital and content marketers in sectors such as FMCG and retail, who are challenged with increasing demand for more content and creating personalised content to meet the demands of their customers. Doing more in the digital space. Robb DeFilippis. A modular content ecosystem.

article thumbnail

Pharma By The Numbers: A Retrospective Look at the Industry and 20 Years of Xtalks History

XTalks

2014 saw multiple business unit buyouts in the industry, with Novartis acquiring GlaxoSmithKline’s oncology arm and Bayer taking over Merck’s consumer health business. In turn, GSK regained full control of its joint consumer health business with Novartis in 2018. In 2015, Pfizer acquired Hospira.